Healthcare [ 5/11 ] | Drug Manufacturers—Specialty & Generic [ 32/112 ]
US | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 11, 23 | -5.91 Increased by +26.13% | -7.50 Increased by +2.83% |
| Mar 22, 23 | -5.00 Increased by +30.56% | -11.50 Increased by +4.91% |
| Nov 7, 22 | -0.53 Increased by +93.38% | -0.44 Decreased by -46.49% |
| Aug 11, 22 | -2.71 Increased by +66.13% | -3.70 Increased by +7.23% |
| Mar 30, 22 | -8.00 Increased by 0.00% | -6.00 Decreased by -5.56% |
| Nov 2, 21 | -7.20 Increased by 0.00% | -7.70 Increased by +0.84% |
| Jul 26, 21 | -8.00 Decreased by -66.67% | -8.64 Increased by +0.86% |
| May 4, 21 | -8.00 Decreased by -100.00% | -8.56 Increased by +0.76% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 23 | 3.81 M Increased by +116.52% | -3.61 M Increased by +69.33% | Decreased by -94.68% Increased by +85.83% |
| Dec 31, 22 | 4.00 M Increased by +164.11% | -13.28 M Increased by +45.48% | Decreased by -332.31% Increased by +79.36% |
| Sep 30, 22 | 3.00 M Increased by +133.26% | -22.05 M Decreased by -31.46% | Decreased by -734.48% Increased by +43.64% |
| Jun 30, 22 | 2.13 M Increased by +79.41% | -13.04 M Increased by +26.06% | Decreased by -613.36% Increased by +58.79% |
| Mar 31, 22 | 1.76 M Increased by +1.42 K% | -11.77 M Increased by +31.29% | Decreased by -668.31% Increased by +95.47% |
| Dec 31, 21 | 1.51 M Increased by +102.00% | -24.36 M Decreased by -38.23% | Decreased by -1.61 K% Increased by +31.57% |
| Sep 30, 21 | 1.29 M Increased by +N/A% | -16.77 M Decreased by -8.04% | Decreased by -1.30 K% Decreased by N/A% |
| Jun 30, 21 | 1.19 M Increased by +N/A% | -17.64 M Decreased by -62.91% | Decreased by -1.49 K% Decreased by N/A% |
Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.